Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in PCD pharma franchise in Hyderabad

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharmaceutical manufacturing company in Mumbai

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in diabetic care pharma franchise in Pune

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharma suppliers in Delhi

Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharma export companies in Kolkata
Dapagliflozin 10mg + Metformin Hydrochloride 500mg Tablet in pharma franchise opportunities in Bengaluru

Dapa M Tablets

Composition : Dapagliflozin 10mg + Metformin Hydrochloride I.P. 500mg Tablets

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Please Contact For Best Price

Dapa M Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin, a biguanide antidiabetic agent. This formulation is used in the management of Type 2 Diabetes Mellitus by improving glycemic control. Dapagliflozin reduces glucose reabsorption in the kidneys, promoting urinary glucose excretion, while Metformin decreases hepatic glucose production and enhances insulin sensitivity. Together, they help in maintaining blood sugar levels and support cardiovascular and renal health in diabetic patients.

Read More

About the Product

Dapa M Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin, a biguanide antidiabetic agent. This formulation is used in the management of Type 2 Diabetes Mellitus by improving glycemic control. Dapagliflozin reduces glucose reabsorption in the kidneys, promoting urinary glucose excretion, while Metformin decreases hepatic glucose production and enhances insulin sensitivity. Together, they help in maintaining blood sugar levels and support cardiovascular and renal health in diabetic patients.

Common side effects may include urinary tract infections, genital infections, nausea, diarrhea, abdominal discomfort, and increased urination. Rarely, hypoglycemia may occur, especially when combined with other antidiabetic drugs.

Indicated for patients with Type 2 Diabetes Mellitus when diet, exercise, and Metformin monotherapy do not provide adequate glycemic control. Also suitable as part of combination therapy for better blood sugar management.

Not recommended for patients with Type 1 diabetes or diabetic ketoacidosis. Caution is advised in patients with renal impairment. Adequate hydration should be maintained to reduce the risk of dehydration.

Get in Touch